|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Comparative acceptability of combined and progestin-only injectable |
| Ruminjo JK; Sekadde-Kigondu CB; Karanja JG; Rivera R; Nasution M |
| Contraception. 2005;72:138-145. |
| We compared 12-month continuation rates, menstrual bleeding patterns and other aspects of acceptability between |
| users of Cyclofem and users of Depo-Provera. The life-table method was used to calculate quarterly continuation |
| rates. In all, 360 Kenyan women were randomly assigned to one of the two contraceptives. User-satisfaction |
| questionnaires were administered at 6 and 12 months or at discontinuation, whichever occurred first. The 1-year |
| continuation rate was 75.4% for Depo-Provera users versus 56.5% for Cyclofem users (p < .001). Main reasons for |
| discontinuation included difficulty making clinic visits (45.1% for Cyclofem vs. 40% for Depo-Provera), menstrual |
| changes (14.1% vs. 12.5%) and nonmenstrual problems (15.5% vs. 12.5%). None of the Depo-Provera users and 8.5% |
| of the Cyclofem users claimed frequency of visits as the main reason for discontinuation. In all, 70.6% of the Depo- |
| Provera users were amenorrheic after 12 months, as were 20.8% of the Cyclofem users. The 1-year continuation rate |
| was higher for Depo-Provera than for Cyclofem. There was no important difference in discontinuation rates because |
| of menstrual problems; the difference mainly reflected the frequency of visits required. (PubHealth.info Document ID: |
| PubHealth.info NOTE: The author(s) of this article titled, "Comparative acceptability of combined and progestin-only |
| injectable contraceptives in Kenya.", is(are) Ruminjo JK; Sekadde-Kigondu CB; Karanja JG; Rivera R; Nasution |
| M. The source of this article is "Contraception. 2005;72:138-145.". This article was published in 2005 in English |
| language(s). (PubHealth.info® Document ID: CONT1T 85-06. All rights reserved with PubHealth.info) PIN: 85 |
| This article is peer-reviewed. |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |